Mesothelioma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

77 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mesothelioma
NCT05627960: First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

Recruiting
1a
77
US
AG-01 Compound
A&G Pharmaceutical Inc., University of Maryland Greenebaum Cancer Center
Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
06/26
11/26
ACTRN12624000268549: LEPO: A phase 1 study of Leptospermum petersonii extract for patients with mesothelioma

Not yet recruiting
1
18
 
ADDRI, Insurance and Care NSW
Mesothelioma
 
 
ACTRN12609000260224: Optimising regulatory T cell depletion with cyclophosphamide in combination with chemotherapy for enhanced anti-tumour immunity in patients with non-small cell lung cancer (NSCLC) and malignant mesothelioma (MM).

Recruiting
1
33
 
Sir Charles Gairdner Hospital, National Health and Medical Research Council (NHMRC)
Malignant Mesothelioma, Non small cell lung cancer
 
 
ACTRN12614001248651: The first testing of TargomiRs in the human setting: dose-finding studies in patients with recurrent malignant pleural mesothelioma and non-small cell lung cancer

Recruiting
1
30
 
Asbestos Disease Research Institute, Asbestos Disease Research Foundation, EnGeneIC
Malignant Pleural Mesothelioma , Advanced Non Small Cell Lung Cancer
 
 
ACTRN12609000294257: CD-40 activating antibody (CP-870,893) in combination with cisplatin and pemetrexed in unresectable malignant mesothelioma: a phase Ib study

Completed
1
15
 
Sir Charles Gairdner Hospital, Pfizer Australia (research grant-in-aid for investigator initiated study)
unresectable malignant pleural mesothelioma
 
 
ChiCTR-OIC-16007996: Open-label, uncontrolled, single-arm pilot study to evaluate cellular immunotherapy using mesothelin-targeted chimeric antigen receptor engineered T cells in patients with mesothelin+ malignant pleural mesothelioma and pancreatic carcinoma.

Not yet recruiting
1
30
 
anti-meso CART cells
Renji Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai GeneChem Co., Ltd., Shanghai GeneChem Co.,Ltd.
malignant pleural mesothelioma and pancreatic carcinoma
 
 
NCT04034238: Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Completed
1
19
US
LMB-100, Tofacitinib, Xeljanz, Mesothelin Expression
National Cancer Institute (NCI)
Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic, Adenocarcinoma, Pancreatic
12/20
11/21
CK-301-101, NCT03212404: Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Recruiting
1
500
Europe, RoW
CK-301 (cosibelimab)
Checkpoint Therapeutics, Inc., Novotech (Australia) Pty Limited
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced, Head and Neck Cancer, Melanoma, Merkel Cell Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma, Classical Hodgkin Lymphoma, Cutaneous Squamous Cell Carcinoma, Non Hodgkin Lymphoma, Endometrial Cancer
11/21
12/24
NCT02637531: A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Checkmark From MARIO-1 trial in combination with IPI-549 for solid tumors
Nov 2020 - Nov 2020: From MARIO-1 trial in combination with IPI-549 for solid tumors
Checkmark From P1/1b trial in combination with IPI-549 for advanced solid tumors
Nov 2020 - Nov 2020: From P1/1b trial in combination with IPI-549 for advanced solid tumors
Checkmark Clinical & translational data from expansion cohorts of MARIO‑1 phase 1b study in combination with Opdivo
More
Active, not recruiting
1
219
US
IPI-549 (eganelisib), Nivolumab, OPDIVO
Infinity Pharmaceuticals, Inc.
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
01/22
12/22
MESOVAX, NCT03546426: Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies

Recruiting
1
18
Europe
Pembrolizumab, Autologous dendritic cells, Interleukin-2
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Mesothelioma, Malignant, PD-L1 Negative, Advanced Cancer, Progressive Disease
01/22
01/24
NCT04345705: Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma

Not yet recruiting
1
18
US
Poly ICLC, Hiltonol®
Raja M Flores, Oncovir, Inc.
Mesothelioma
05/22
05/22
NCT04489862: αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Recruiting
1
10
RoW
αPD1-MSLN-CAR T cells
Wuhan Union Hospital, China, Shanghai Cell Therapy Group Co.,Ltd
Non-small-cell Lung Cancer, Mesothelioma
06/22
12/22
LuPARP, NCT04375267: 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

Active, not recruiting
1
18
Europe
177Lu-DOTA-TATE + olaparib
Vastra Gotaland Region, Advanced Accelerator Applications
Clinical Trial, Phase I, Neuroendocrine Tumors, Thymoma, Mesothelioma
06/24
06/24
8479217, NCT06469138: A Phase 1 Study to Investigate 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects

Completed
1
6
Europe
Bemcentinib, BGB324
BerGenBio ASA
Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Metastatic Pancreatic Cancer, Glioblastoma, Malignant Mesothelioma, COVID-19
09/22
09/22
NCT03852823: Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Recruiting
1
192
RoW
SG001, Recombinant Human Anti-PD-1 Monoclonal Antibody
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumours, Cervical Cancer, Malignant Mesothelioma, Lymphoma, Non-Small-Cell Lung Cancer
09/22
03/23
NCT03228537: Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Active, not recruiting
1
28
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Extrapleural Pneumonectomy, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Pleurectomy, Excision of Pleura, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v7, Stage IA Pleural Malignant Mesothelioma AJCC v7, Stage IB Pleural Malignant Mesothelioma AJCC v7, Stage II Pleural Malignant Mesothelioma AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7
10/22
09/24
NCT04042480: A Study of SGN-CD228A in Advanced Solid Tumors

Terminated
1
88
Europe, US
SGN-CD228A
Seagen Inc.
Cutaneous Melanoma, Pleural Mesothelioma, HER2 Negative Breast Neoplasms, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
03/23
03/23
NCT04537715: Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer

Completed
1
42
Europe, US
Tazemetostat, EPZ-6438, Tazverik, Itraconazole, Sporanox, Rifampin, RIF, Rifampicin, Rifadin, Rimactane
Epizyme, Inc.
All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor, Follicular Lymphoma (FL), Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), Epithelioid Sarcoma (ES), Synovial Sarcoma, Renal Medullary Carcinoma, Mesothelioma, Rhabdoid Tumor
04/23
04/23
MESO-PRIME, NCT04166734: Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma

Terminated
1
3
Europe
Pembrolizumab, Keytruda, Stereotactic Body Radiotherapy (SBRT), SBRT
Royal Marsden NHS Foundation Trust, Merck Sharp & Dohme LLC
Advanced Malignant Pleural Mesothelioma
07/23
07/23
NCT04525859: Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma

Recruiting
1
19
US
Safety, Expansion Cohort
Oncovir, Inc., Icahn School of Medicine at Mount Sinai
Malignant Pleural Mesothelioma
08/23
08/24
DIONE-01, NCT04328844: A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Active, not recruiting
1
210
Europe
IOA-244, Avelumab Injection, Pemetrexed, Cisplatin, Ruxolitinib
iOnctura
Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis, Uveal Melanoma
09/23
04/24
PITHAC, NCT06281860: Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration

Recruiting
1
39
Europe
Cisplatine Teva®, Procedure/Surgery
Dr Jean Yannis PERENTES
Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma Breast Stage IV, Ovarian Cancer, Esophageal Cancer, Gastric Cancer
12/25
02/26
NCT03590054: Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Checkmark Interim data in combination with abexinostat for multiple solid tumors
Aug 2019 - Aug 2019: Interim data in combination with abexinostat for multiple solid tumors
Completed
1
35
US
Abexinostat, PCI-24781, Pembrolizumab, Keytruda
Rahul Aggarwal, Xynomic Pharmaceuticals, Inc.
Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Non-Small Cell Lung Carcinoma, Stage IB Lung Cancer AJCC v7, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
11/23
11/23
NCT03420963: Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Recruiting
1
38
US
Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Allogeneic CB-derived Ex vivo-expanded NK Cells, CB-derived Expanded Allogeneic NK Cells, UCB-derived Expanded Allogeneic NK Cells, Umbilical Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Male Reproductive System Neoplasm, Recurrent Malignant Mesothelioma, Recurrent Malignant Neoplasm of Multiple Primary Sites, Recurrent Malignant Oral Neoplasm, Recurrent Malignant Pharyngeal Neoplasm, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Soft Tissue Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Thyroid Gland Neoplasm, Recurrent Malignant Urinary System Neoplasm, Refractory Cutaneous Melanoma, Refractory Malignant Bone Neoplasm, Refractory Malignant Endocrine Neoplasm, Refractory Malignant Female Reproductive System Neoplasm, Refractory Malignant Male Reproductive System Neoplasm, Refractory Malignant Mesothelioma, Refractory Malignant Neoplasm of Multiple Primary Sites, Refractory Malignant Oral Neoplasm, Refractory Malignant Pharyngeal Neoplasm, Refractory Malignant Skin Neoplasm, Refractory Malignant Soft Tissue Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Malignant Thyroid Gland Neoplasm, Refractory Malignant Urinary System Neoplasm
12/27
12/27
AURELIO-03, NCT04234113: Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Active, not recruiting
1
200
Europe, US, RoW
SO-C101, SOT101, pembrolizumab
SOTIO Biotech AG, SOTIO Biotech a.s.
Thyroid, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma, Microsatellite Instability High, Triple Negative Breast Cancer, Mesothelioma, Thymic Cancer, Cervical Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer
08/24
11/24
NCT02748798: Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders

Recruiting
1
160
Canada
HP 3He, Hyperpolarized helium 3, HP 129Xe, Hyperpolarized xenon 129, PFP, Perfluoropropane, SF6, Sulfur hexafluoride, 129Xe Small and Large Human Lung Coil, 3He Human Lung Coil, PFP and SF6 Human Lung Coil
Thunder Bay Regional Health Research Institute, Thunder Bay Regional Health Sciences Centre, St. Joseph's Care Group, Lakehead University
Lung Transplant, Lung Resection, Lung Cancer, Asthma, Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, Emphysema, Mesothelioma, Asbestosis, Pulmonary Embolism, Interstitial Lung Disease, Pulmonary Fibrosis, Bronchiectasis, Seasonal Allergies, Cold Virus, Lung Infection, Pulmonary Hypertension, Pulmonary Dysplasia, Obstructive Sleep Apnea
12/23
12/23
NCT04491942: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Active, not recruiting
1
74
Canada, US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011
National Cancer Institute (NCI)
Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma, Advanced Endometrial Carcinoma, Advanced Esophageal Carcinoma, Advanced Gastric Carcinoma, Advanced Head and Neck Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Penile Carcinoma, Advanced Pleural Malignant Mesothelioma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Intrahepatic Bile Duct Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Pleural Malignant Mesothelioma AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Pleural Malignant Mesothelioma AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma
06/25
06/25
NCT01766739: Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Active, not recruiting
1
18
US
GL-ONC1
Memorial Sloan Kettering Cancer Center, Genelux Corporation
Lung Cancer
01/25
01/25
NCT05498597: AMT-151 in Patients With Selected Advanced Solid Tumours

Recruiting
1
30
RoW
AMT-151
Multitude Therapeutics Inc., Tigermed Consulting Co., Ltd
Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer, Ovarian Carcinoma, Ovarian Epithelial Cancer, Ovarian Endometrioid Adenocarcinoma, Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Lung Adenocarcinoma, Triple Negative Breast Cancer, Pancreatic Ductal Adenocarcinoma, Malignant Pleural Mesothelioma, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Mucinous Adenocarcinoma
01/24
10/24
NCT04840615: Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Terminated
1
2
US
LMB-100, ipilimumab, Yervoy, Diphenhydramine, Benadryl, Famotidine, Pepcid, Acetaminophen, Tylenol, Dexamethasone, Ozurdex, Biopsy, FDG-PET, Fluorodeoxyglucose-positron emission tomography, CT CAP, Computed tomography of the chest, abdomen and pelvis, MRI, Magnetic resonance imaging, ECG, Electrocardiogram, Echocardiogram, Echo
National Cancer Institute (NCI)
Mesothelioma
12/21
01/22
KEYNOTE-E13, NCT05215574: Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Recruiting
1
130
US
NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
NGM Biopharmaceuticals, Inc, Merck Sharp & Dohme LLC
Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Carcinoma, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
07/25
03/26
KEYNOTE-E20, NCT05311618: Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Active, not recruiting
1
71
US
NGM438, Pembrolizumab (KEYTRUDA ®)
NGM Biopharmaceuticals, Inc, Merck Sharp & Dohme LLC
Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Cancer, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
04/25
06/25
UCMYM802-Ⅰ, NCT06256055: Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

Recruiting
1
24
RoW
UCMYM802 Injection
UTC Therapeutics Inc., Peking University Cancer Hospital & Institute
Malignant Mesothelioma, Colorectal Cancer, Bile Duct Cancer, Rectal Cancer, Ovary Cancer, Pancreatic Cancer, Breast Cancer Female
03/25
04/25
NCT02959463: Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Active, not recruiting
1
24
US
Laboratory Biomarker Analysis, Palliative Radiation Therapy, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Pleural Malignant Mesothelioma
04/24
04/24
NCT06299163: NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

Recruiting
1
180
US
NM32-2668
Numab Therapeutics AG
Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer, Adenocarcinoma of Lung, Triple Negative Breast Cancer, Liposarcoma, Leiomyosarcoma, Mesothelioma, Malignant, Adenocarcinoma - Gastroesophageal Junction (GEJ), Adenocarcinoma of the Stomach, Melanoma, Malignant, Renal Cell Carcinoma
12/27
12/27
NCT06196294: GPC3/Mesothelin-CAR-γδT Cells Against Cancers

Recruiting
1
30
RoW
Cell therapy for solid tumors
Second Affiliated Hospital of Guangzhou Medical University
Pancreas Cancer, Lung Cancer, Liver Cancer, Mesothelioma, CAR-T Cell Therapy, Solid Tumor, Adult
11/30
12/36
BGC515-101, NCT06452160: A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

Recruiting
1
103
US
BGC515
BridGene Biosciences Inc.
Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
06/27
12/27
NCT04040231: Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Active, not recruiting
1
10
US
Galinpepimut-S, Nivolumab, Sargramostim, GM-CSF
Memorial Sloan Kettering Cancer Center
Mesothelioma, Pleural Mesothelioma, Wilms Tumor
07/24
07/24
TEAD-AST-101, NCT06251310: SW-682 in Advanced Solid Tumors

Recruiting
1
186
US
SW-682, Combination Therapy
SpringWorks Therapeutics, Inc.
Advanced Solid Tumor, Mesothelioma, Malignant
01/30
06/30
NCT03715933: Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
240
US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx, Inc.
Solid Tumors, Malignant Pleural Mesothelioma, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Sarcoma, Pancreatic Adenocarcinoma, Ewing Sarcoma, Chondrosarcoma, GIST, SDH-deficient Solid Tumors
12/25
07/26
STEALTH-001, NCT06444815: A Study of VET3-TGI in Patients With Solid Tumors

Not yet recruiting
1
60
NA
VET3-TGI, Pembrolizumab
KaliVir Immunotherapeutics
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer
09/27
12/27
NCT06466187: A Study of SGN-MesoC2 in Advanced Solid Tumors

Not yet recruiting
1
365
NA
SGN-MesoC2, HBM9033
Seagen Inc.
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors
11/28
11/28
NX-1607-101, NCT05107674: A Study of NX-1607 in Adults With Advanced Malignancies

Recruiting
1
345
Europe, US
NX-1607, Cbl-b Inhibitor, Paclitaxel
Nurix Therapeutics, Inc.
Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
08/24
02/26
NCT04577326: Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Recruiting
1
30
US
cyclophosphamide, CAR T cells
Memorial Sloan Kettering Cancer Center, Atara Biotherapeutics
Malignant Pleural Mesothelioma (MPM)
09/25
09/25
NCT05071014: A Study of Pembrolizumab and Cryoablation in People With Mesothelioma

Completed
1
2
US
Pembrolizumab, Image-guided cryoablation
Memorial Sloan Kettering Cancer Center
Lung Cancer, Unresectable Mesothelioma
12/23
12/23
NCT05415098: Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Recruiting
1
90
US
APG-5918
Ascentage Pharma Group Inc.
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma, Mesothelioma, Sarcoma, Non Hodgkin Lymphoma, B Cell Lymphoma, Epithelioid Sarcoma
09/24
09/25
NCT05228015: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Active, not recruiting
1
198
Europe, US
IK-930, Osimertinib
Ikena Oncology
Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE), NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes, NF2 Deficiency, YAP1 or TAZ Gene Fusions
06/25
06/25
NCT03556228: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Recruiting
1
74
US
VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
VM Oncology, LLC
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Mesothelioma, Thymic Carcinoma, Cervical Cancer, Ovarian Cancer, Bladder Cancer, Esophageal Cancer, Uterine Cancer, Sarcoma, Any Solid Tumors Progressed After a Prior Immunotherapy
12/25
06/26
HFB-200301-01, NCT05238883: A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Recruiting
1
170
Europe, US
HFB200301, Tislelizumab, BGB-A317
HiFiBiO Therapeutics
Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Testicular Germ Cell Tumor, Cervical Cancer, Mesothelioma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
12/26
12/26
NCT05538572: A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Completed
1
22
US, RoW
PRT3645
Prelude Therapeutics
Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma, Non-small Cell Lung Cancers, Sarcoma, Endometrial Cancer
06/24
06/24
ENSURE, NCT05304208: dENdritic Cell Therapy Combined With SURgEry in Mesothelioma

Recruiting
1
16
Europe
Mesopher
Erasmus Medical Center
Mesotheliomas Pleural
12/24
12/25
NCT03760575: Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Recruiting
1
20
US
Pembrolizumab, MK-3475, Indocyanine Green (ICG) Image-Guided Surgery, Cisplatin, Pemetrexed
Abramson Cancer Center at Penn Medicine
Mesotheliomas Pleural
12/24
12/24
NCT03917043: APG-2449 in Patients With Advanced Solid Tumors

Recruiting
1
150
RoW
APG-2449, APG-2449 Capsule
Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.
Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma
01/25
02/25
TOAST IT, NCT04213794: Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

Recruiting
1
43
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cytoreductive Surgery, Cytoreduction, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Hyperthermic Intraperitoneal Chemotherapy, HIPEC, Sodium Thiosulfate, Cyanide Antidote Package, Disodium Thiosulfate, S-Hydril, Sodium Hyposulfate, Sodium Thiosulfate Pentahydrate, Sodium Thiosulphate, Sodothiol, Thiosulfate, Sodium, Pentahydrate, Thiosulfuric Acid Disodium Salt, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computed Tomography (CT), CT Scan, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MRI, MRI Scan, Nuclear Magnetic Resonance Imaging, NMRI, Structural MRI, sMRI, Positron Emission Tomography, Medical Imaging, PET, PET Scan, positron emission tomography scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection
Mayo Clinic, National Cancer Institute (NCI)
Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm, Recurrent Colon Carcinoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Gastric Carcinoma, Recurrent Liposarcoma, Recurrent Malignant Mesothelioma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Rectal Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Sarcoma, Refractory Colon Carcinoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Fallopian Tube Carcinoma, Refractory Gastric Carcinoma, Refractory Liposarcoma, Refractory Malignant Mesothelioma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Refractory Rectal Carcinoma, Refractory Rhabdomyosarcoma, Refractory Sarcoma, Resectable Liposarcoma, Resectable Malignant Mesothelioma, Resectable Sarcoma
01/25
01/25
KEYNOTE-E65, NCT03881488: Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Recruiting
1
157
US
CTX-471, Pembrolizumab (KEYTRUDA®), KEYTRUDA®
Compass Therapeutics, Iqvia Pty Ltd, Merck, Sharp & Dohme, LLC, Rahway, NJ USA
Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
02/25
04/25
NCT03054298: CAR T Cells in Mesothelin Expressing Cancers

Active, not recruiting
1
65
US
huCART-meso cells
University of Pennsylvania, National Institutes of Health (NIH), Tmunity Therapeutics, a wholly owned subsidiary of Kite Pharma (a Gilead company)
Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma, Fallopian Tube Cancer, Mesotheliomas Pleural, Mesothelioma Peritoneum
03/25
03/25
NCT04836429: Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease

Suspended
1
16
US
Porfimer Sodium, 87806-31-3, CL-184116, Dihematoporphyrin Ester, Photofrin II, Video-Assisted Thoracic Surgery, VATS, Photodynamic Therapy, PDT, Intraoperative PDT, intra-operative photo dynamic therapy
Roswell Park Cancer Institute
Lung Non-Small Cell Carcinoma, Pleural Disorder
03/25
03/25
NCT03678350: Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

Active, not recruiting
1
9
US
Light Dosimetry for Intranoperative Therapy, Photodynamic Therapy, PDT, Photoradiation Therapy, Porfimer Sodium, CL-184116, DHE, Dihematoporphyrin Ester, dihematoporphyrin ether, Photofrin II
Roswell Park Cancer Institute, Lumeda,Inc.
Malignant Mesothelioma, Non-Small Cell Lung Carcinoma, Pleural Disorder
11/23
11/25
NCT03983954: Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

Hourglass Jan 2021 - Mar 2021 : First safety data from P1b trial in combination with Imfinzi for solid tumors
Hourglass Oct 2020 - Dec 2020 : Completion of P1b portion of p1b/2 trial in combination with Imfinzi for solid tumors
Active, not recruiting
1
60
RoW
Obinutuzumab pretreatment (Gazyva®) Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736), Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)
NeoTX Therapeutics Ltd., AstraZeneca
ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma, Endometrial Cancer, Renal Cell Carcinoma, Urothelial Cancer, Head and Neck Squamous Cell Carcinoma, Mesothelioma, Melanoma, Hepatocellular Carcinoma, Prostate Cancer, NSCLC, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Colorectal Cancer Metastatic, GastroEsophageal Cancer, NSCL2 Gene Mutation
10/26
10/26
NCT05904496: A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813

Active, not recruiting
1
37
Europe, US, RoW
BGB-30813, Tislelizumab, BGB-A317
BeiGene
Advanced Solid Tumors
05/25
05/26
NCT04857372: A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

Recruiting
1
156
Europe, Canada, Japan, US, RoW
IAG933
Novartis Pharmaceuticals
Mesothelioma
10/25
10/25
NCT04926948: Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma

Active, not recruiting
1
20
US
Immunotherapy, Immunological, Immunological Therapy, Immunologically Directed Therapy, Quality-of-Life Assessment, Quality of Life Assessment, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
Mayo Clinic, National Cancer Institute (NCI)
Pleural Mesothelial Neoplasm
05/25
05/26
NCT04242199: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Active, not recruiting
1
182
Europe, Japan, US, RoW
INCB099280
Incyte Corporation
Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, HepatoCellular Carcinoma, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma
07/25
10/25
MK-4830-001, NCT03564691: Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors

Checkmark Data from a trial in combination with MK-4830 for solid tumor
Sep 2020 - Sep 2020: Data from a trial in combination with MK-4830 for solid tumor
Active, not recruiting
1
442
Europe, Canada, Japan, US, RoW
MK-4830, Pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®, Carboplatin, Paraplatin, Pemetrexed, ALIMTA®, Pleumet, Pemecad, Lenvatinib, LENVIMA®, Lenvanix, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Cisplatin, Platinol®, Platinol®-AQ, CDDP, MK-4830A
Merck Sharp & Dohme LLC
Neoplasms
09/25
09/25
SGNBB228-001, NCT05571839: A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Recruiting
1
275
Europe, Canada, US
SGN-BB228
Seagen Inc.
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
10/25
09/28
PEMBIB, NCT02856425: Trial Of Pembrolizumab And Nintedanib

Recruiting
1
221
Europe
Nintedanib, Pembrolizumab
Gustave Roussy, Cancer Campus, Grand Paris
Patients With Any Advanced Solid Tumors
11/25
11/28
NCT04162015: A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma

Active, not recruiting
1
22
US
Nivolumab, Pemetrexed, Cisplatin or Carboplatin
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb
Malignant Pleural Mesothelioma
11/25
11/25
NCT02707666: A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

Recruiting
1
15
US
Pembrolizumab, Cisplatin and Pemetrexed
University of Chicago
Pleural Mesothelioma
12/25
12/25
CAMP1, NCT05698238: Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours

Not yet recruiting
1
50
NA
CA9hu-1
Mabpro, a.s.
Clear Cell Renal Cell Carcinoma Metastatic, TNBC - Triple-Negative Breast Cancer, Head and Neck Cancer, Non-small-cell Lung Carcinoma, Mesothelioma, Malignant
01/26
01/27
NCT04272034: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Active, not recruiting
1
105
Europe, US
INCB099318
Incyte Corporation
Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma, Cyclin-dependent Kinase 12 Mutated Tumors, Basal Cell Carcinoma (Unresectable or Metastatic), Sarcomatoid Renal Cell Carcinoma, Clear Cell Ovarian or Endometrial Carcinoma, Anal Carcinoma, Squamous Cell Penile Carcinoma, DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)
01/26
06/26
NCT05544929: A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Recruiting
1
180
Europe, Canada, Japan, US, RoW
KFA115, NVP-KFA115, pembrolizumab, Keytruda
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms
02/26
02/26
NCT05568680: SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Recruiting
1
42
US
SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
Verismo Therapeutics
Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant
03/26
03/26
NCT05298592: A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors

Active, not recruiting
1
154
Europe, Japan, US, RoW
BMS-986406, Nivolumab, BMS-936558, Opdivo, Carboplatin, Pemetrexed, Paclitaxel
Bristol-Myers Squibb
Advanced Cancer
08/24
08/24
NCT06034860: Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Recruiting
1
200
US
MT-8421, Nivolumab
Molecular Templates, Inc.
Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
07/26
10/26
NCT04897022: A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma

Recruiting
1
24
US
Pembrolizumab, IMPRINT, intensity-modulated pleural radiation therapy
Memorial Sloan Kettering Cancer Center
Malignant Pleural Mesothelioma
08/26
08/26
NCT05375825: Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

Not yet recruiting
1
42
US
Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin
National Cancer Institute (NCI)
Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant, Pleural Effusions, Malignant, Mesothelin (Msln)
12/24
12/24
NCT04847063: Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies

Recruiting
1
60
US
Mitomycin C, Cisplatin, Heated Intraperitonial Chemotherapy, Doxorubicin, Oxaliplatin, 5-Fluorouracil, Sodium Thiosulfate
National Cancer Institute (NCI)
Peritoneal Carcinomatosis, Peritoneal Mesothelioma, Ovarian Cancer, Gastrointestinal Cancer, Appendiceal Cancer
12/30
12/31

Download Options